- |||||||||| Rituxan (rituximab) / Roche
Journal, IO biomarker: Rituximab in Refractory Myasthenia Gravis - Challenges and Lessons Learnt. (Pubmed Central) - Dec 2, 2024
One patient who had no response to therapy was re-evaluated and diagnosed with congenital myasthenic syndrome related to biallelic CHRNE mutation. In summary, nearly two-thirds (7/11, 63.6%) of autoimmune refractory MG in this cohort showed a good response to rituximab.
- |||||||||| Journal: Ileus at Altitude. (Pubmed Central) - Dec 2, 2024
Presented here is a case study that exemplifies GI symptoms in MG, exacerbated by low barometric pressure at altitude. This illustrates the need to identify GI symptoms earlier in MG patients, as well as the need for providers at high altitude to be aware of these manifestations of MG.
- |||||||||| Bridion (sugammadex) / Merck (MSD)
Review, Journal: A Review of Muscle Relaxants in Anesthesia in Patients with Neuromuscular Disorders Including Guillain-Barr (Pubmed Central) - Dec 2, 2024
The review highlights the role of reversal agents, particularly sugammadex, as a safer and more effective alternative to traditional acetylcholinesterase inhibitors such as neostigmine...Based on the available literature and the authors' clinical experience, this review aims to discuss the role of muscle relaxants in anesthesia in patients with the aforementioned neuromuscular disorders. This document uses the latest possible articles, covering items from 1992 to 2024.
- |||||||||| Journal: Nomogram for predicting pregnancy-related relapse of myasthenia gravis. (Pubmed Central) - Dec 2, 2024
The first trimester of pregnancy and three months following delivery or abortion are high-risk periods for MG relapse. Younger ages, shorter MG stable duration before pregnancy, thymic hyperplasia, and inadequate treatments during pregnancy increase relapse risk.
- |||||||||| Journal: Thymectomy via Trans-subxiphoid Approach (Pubmed Central) - Dec 2, 2024
Postoperative pain evaluated using numeric rating scale was minimal and epidural anesthesia is not required. Furthermore, we herein describe thoracoscopic subxiphoid-optical thymectomy based on the RST for institutes where thoracic robotic surgery has not been adopted.
- |||||||||| Review, Journal, CAR T-Cell Therapy, IO biomarker: Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review. (Pubmed Central) - Nov 29, 2024
CAR-T cell therapy is a paradigm shift in managing rheumatologic diseases, with symptomatic improvement and biochemical control of these diseases. Although preliminary evidence indicates promising results, long-term follow-up and prospective clinical trials are needed to establish optimal timing and assess the safety and efficacy of CAR-T immunotherapy.
- |||||||||| Journal: Thyroid eye disease and ocular myasthenia gravis. (Pubmed Central) - Nov 28, 2024
Emerging therapies and diagnostic techniques should be integrated into practice. Further research is warranted to explore the long-term safety and efficacy of novel treatments and the potential genetic links between these conditions.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Review, Journal, Adverse events: Ocular Immune-Related Adverse Events Associated with PD-1 Inhibitors: From Molecular Mechanisms to Clinical Management. (Pubmed Central) - Nov 28, 2024
With the increasing use of PD-1 inhibitors, ophthalmologists need to remain sensitive to the clinical manifestations of adverse events to ensure timely diagnosis and management. To improve their quality of life and reduce mortality, oncologists and ophthalmologists should maintain close cooperation and implement multi-disciplinary treatment.
- |||||||||| Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) / argenx, Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
Review, Journal: Efgartigimod: A Review in Generalised Myasthenia Gravis. (Pubmed Central) - Nov 28, 2024
Efgartigimod was generally well tolerated; the most common adverse events were headache and infections (with IV efgartigimod) and injection-site reactions (with SC efgartigimod PH20). Although further long-term data are required, IV and SC formulations of efgartigimod provide effective, generally well-tolerated and flexible treatment options for adults with AChR Ab+ gMG.
- |||||||||| Journal: Early stage thymoma and the surgical extent paradigm. (Pubmed Central) - Nov 27, 2024
None of the factors including surgical extent analysed with univariate and multivariate analysis had a significant effect on FFR. Limited thymectomy may be a good treatment option for non-myasthenic early stage thymoma patients but randomized controlled trials with long follow-up periods, ideally comparing patients operated with minimally invasive surgery are necessary.
- |||||||||| Journal: The Urban-Rural Divide in Neurocritical Care in Low-Income and Middle-Income Countries. (Pubmed Central) - Nov 26, 2024
The rural areas of LMICs bear the maximum impact because of their limited access to preventive health services, high incidence of acquired brain injury, inability to have timely management of neurological emergencies, and scarcity of specialist services in a resource-deprived health center. An increase in the health budget allocation for rural areas, NCC education and training of the workforce, and provision of telemedicine services for rapid diagnosis, management, and neurorehabilitation are some of the steps that can be quite helpful.
- |||||||||| nipocalimab (M281) / J&J
Review, Journal: What Is in the Neuromuscular Junction Literature? (Pubmed Central) - Nov 26, 2024
A number of studies on the newer treatments are discussed including a phase 2 trial of nipocalimab and recommendations for using some of these drugs...A study on the incidence of taste disorders and alopecia in MG follows. The update ends with the topic of the burden of disease in MG and Lambert-Eaton myasthenic syndrome.
- |||||||||| Development and Evaluation of a Contraception Curriculum for Neurology Residents (South Hall H - Level 1 - LACC) - Nov 26, 2024 - Abstract #AES2024AES_1070;
This small, pilot curriculum that taught neurology residents about contraception was successful in increasing knowledge and conversations about contraception. Specifically, neurology residents felt significantly more comfortable talking to patients about combined hormonal contraception, which has many drug-drug interactions with anti-seizure medications.
- |||||||||| Rituxan (rituximab) / Roche
Retrospective data, Journal: Retrospective Analysis of Rituximab Therapy for Myasthenia Gravis: A Case Series. (Pubmed Central) - Nov 26, 2024
In the three cases included in this analysis, rituximab led to notable improvements in quality of life, general clinical condition, and muscle weakness. Further studies with larger patient populations and longer follow-up periods are needed to validate these results and provide a more comprehensive understanding of rituximab's role in MG treatment.
- |||||||||| Review, Journal, CAR T-Cell Therapy: Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review. (Pubmed Central) - Nov 25, 2024
CAR T cells herald a new era in the therapeutic landscape of neurological disorders. While their application in solid tumors, such as glioblastoma, has not universally yielded robust success, emerging innovative strategies show promise, and there is optimism for their effectiveness in certain autoimmune neurological disorders.
- |||||||||| Journal: Ectopic Thymoma in the Thorax With Associated Myasthenia Gravis. (Pubmed Central) - Nov 22, 2024
Paraneoplastic syndromes are rarely reported in association with ectopic thymoma, making this case unusual. We discuss the nuances of diagnosis, classification, and staging of this rare case, as well as the patient's subsequent management by cardiothoracic surgery and neurology specialists.
- |||||||||| Journal: Morvan's Syndrome with Myasthenia Gravis: An Autoimmune or Paraneoplastic Association? (Pubmed Central) - Nov 21, 2024
Achieving MSE within 6?months, BMI, QMG bulbar muscle score at baseline before steroid treatment, disease duration, and disease relapse may represent crucial influencing factors, which should be considered to improve the long-term prognosis for patients with MG in future studies and practice. No abstract available
- |||||||||| Journal, CAR T-Cell Therapy: Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. (Pubmed Central) - Nov 20, 2024
VGCC antibody titers decrease, resulting in a clinical improvement of LEMS symptoms, e.g., 8-fold increase in walking distance. The patient does not show relevant side effects except for cytokine release syndrome grade 2 and intermittent neutropenia suggesting that anti-CD19 CAR-T cell therapy may be a treatment option in patients with LEMS.
- |||||||||| Journal: Autoimmune retinopathy associated with systemic autoimmune disease: a case series. (Pubmed Central) - Nov 20, 2024
AIR in association with these systemic conditions is rarely reported. Our cases highlight the gaps in our current understanding of the definition, systemic associations, pathogenesis, and management of AIR and the importance of multimodal imaging and a multidisciplinary approach in managing patients with suspected AIR.
- |||||||||| Biomarker, Enrollment open, Trial completion date, Trial primary completion date: Biomarkers in Autoimmune Disease of Nervous System (clinicaltrials.gov) - Nov 20, 2024
P=N/A, N=50000, Recruiting,
Our cases highlight the gaps in our current understanding of the definition, systemic associations, pathogenesis, and management of AIR and the importance of multimodal imaging and a multidisciplinary approach in managing patients with suspected AIR. Not yet recruiting --> Recruiting | Trial completion date: Jun 2034 --> Jul 2027 | Trial primary completion date: Jun 2034 --> Jul 2027
- |||||||||| Journal: Limb-Girdle Type Congenital Myasthenic Syndrome Anticipated With Scoliosis: A Case Report. (Pubmed Central) - Nov 19, 2024
CMS type 12, as seen in our patient, is characterized by weakness of the limb-girdle muscles, which was anticipated with scoliosis. It is important to note that scoliosis is not generally linked to the GFPT1 mutation, and based on our case, it contributed to a broader and more complex clinical presentation.
- |||||||||| Journal: Thymic mass in an elderly male patient with myasthenia gravis: A rare presentation. (Pubmed Central) - Nov 19, 2024
The presented case is of a 70-year-old male patient who presented with complaints of drooping of bilateral eyelids and breathlessness and was diagnosed to have myasthenia gravis and thymic mass. It is uncommon for an elderly patient to present with thymic mass and myasthenia gravis concurrently.
- |||||||||| Journal: Delayed diagnosis of distal myasthenia gravis: a case report. (Pubmed Central) - Nov 19, 2024
Distal myasthenia gravis can present with isolated and transient hand weakness as a lone symptom, and can persist for years before typical myasthenia gravis symptoms appear. The inclusion of myasthenia gravis in the differential diagnosis is necessary in patients with isolated distal weakness.
- |||||||||| Journal: The impact of immune markers on thymectomy prognosis in thymoma-myasthenia gravis. (Pubmed Central) - Nov 18, 2024
Complement C3 level is a crucial predictor for long-term remission in thymoma-associated MG post-thymectomy. Patients with lower C3 levels are more likely to experience MG symptom progression post-surgery compared to those with normal levels, indicating its potential as a key prognostic marker.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal: Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab. (Pubmed Central) - Nov 18, 2024
Treatment consisted of high-dose corticosteroids, intravenous immunoglobulins, sedation with mechanical ventilation, antibiotic coverage, hemodialysis, and sustained low-efficiency daily diafiltration (SLEDD) with CytoSorb or TheraNova membranes, and intra-aortic balloon pump mechanical cardiac support. No tangible improvement in the condition was observed during the whole treatment period and the patient died on the sixth day of intensive care treatment.
|
